Hyperthyroidism and thyroid cancer risk: A population-based cohort study

Experimental and Clinical Endocrinology and Diabetes

Volumn 121, Issue 7, 2013, Pages 402-406

  Yeh, N C ^a   Chou, C W ^a   Weng, S F ^a,b   Yang, C Y ^a   Yen, F C ^a   Lee, S Y ^a   Wang, J J ^a   Tien, K J ^a,b  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

Author keywords

asians; hyperthyroidism; national health insurance; thyroid cancer

Indexed keywords

ADULT; ARTICLE; CANCER INCIDENCE; CANCER RISK; COHORT ANALYSIS; DIABETES MELLITUS; FEMALE; FOLLOW UP; GOUT; HUMAN; HYPERTENSION; HYPERTHYROIDISM; INCOME; MAJOR CLINICAL STUDY; MALE; NATIONAL HEALTH INSURANCE; PRIORITY JOURNAL; TAIWAN; THYROID CANCER;

ADULT; AGED; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTHYROIDISM; INCIDENCE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; TAIWAN; THYROID NEOPLASMS; TIME FACTORS;

EID: 84880051164     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-0033-1341474     Document Type: Article

References (31)

1. Lim D. Y., Cho H. J., Kim J. et al. Luteolin decreases IGF-II production and downregulates insulin-like growth factor-I receptor signaling in HT-29 human colon cancer cells. BMC Gastroenterology: 2012; 12 9 10.1186/1471-230x-12-9
2. Makoto Nakao S. H. Interaction between IGF-1 polymorphisms and overweight for the risk of pancreatic cancer in Japanese. Int J Mol Epidemiol Genet: 2011; 2 354 366
3. Prestwich R. J., Errington F., Hatfield P. et al. The immune system-is it relevant to cancer development, progression and treatment? Clin Oncol (R Coll Radiol): 2008; 20 101 112 S0936-6555(07)00866-7 [pii]10.1016/j.clon.2007.10.011 (Pubitemid 351194288)
4. Means I. The Thyroid and its Diseases. Philadelphia Lippincott: 1937
5. Oertli D., Harder F., Oberholzer M. et al. Hyperthyroidism and thyroid carcinoma - coincidence or association? Schweiz Med Wochenschr: 1998; 128 1910 1914 (Pubitemid 28546888)
6. Gabriele R., Letizia C., Borghese M. et al. Thyroid cancer in patients with hyperthyroidism. Hormone research: 2003; 60 79 83 10.1159/000071875 (Pubitemid 36928674)
7. Calo P. G., Tatti A., Farris S. et al. Differentiated thyroid carcinoma and hyperthyroidism: a frequent association? Chir Ital: 2005; 57 193 197
8. Beahrs O. H., Pemberton Jde J., Black B. M. Nodular goiter and malignant lesions of the thyroid gland. J Clin Endocrinol Metab: 1951; 11 1157 1165
9. Sokal J. E. Incidence of malignancy in toxic and nontoxic nodular goiter. J Am Med Assoc: 1954; 154 1321 1325
10. Shapiro SJF N., Perzik S. L., Catz B. Incidence of thyroid carcinoma in Graves'disease. Cancer: 1970; 26 1261 1270
11. Chou F. F., Sheen-Chen S. M., Chen Y. S. et al. Hyperthyroidism and concurrent thyroid cancer. International surgery: 1993; 78 343 346
12. Chao T. C., Lin J. D., Jeng L. B. et al. Thyroid cancer with concurrent hyperthyroidism. Arch Surg: 1999; 134 130 134
13. Zanella E., Rulli F., Sianesi M. et al. Hyperthyroidism with concurrent thyroid cancer. Annali italiani di chirurgia: 2001; 72 293 297
14. Lin C. H., Chiang F. Y., Wang L. F. Prevalence of thyroid cancer in hyperthyroidism treated by surgery. The Kaohsiung journal of medical sciences: 2003; 19 379 384 10.1016/S1607-551X(09)70480-2
15. Shu X., Ji J., Li X. et al. Cancer risk in patients hospitalised for Graves' disease: a population-based cohort study in Sweden. British journal of cancer: 2010; 102 1397 1399 10.1038/sj.bjc.6605624
16. Franklyn J. A., Maisonneuve P., Sheppard M. et al. Cancer incidence and mortality after radioiodine treatment for hyperthyroidism: a population-based cohort study. Lancet: 1999; 353 2111 2115 S0140-6736(98)12295-X [pii]10.1016/S0140-6736(98)12295-X (Pubitemid 29278480)
17. Ribatti D., Conconi M. T., Nussdorfer G. G. Nonclassic endogenous novel [corrected] regulators of angiogenesis. Pharmacol Rev: 2007; 59 185 205 59/2/185 [pii]10.1124/pr.59.2.3 (Pubitemid 46855439)
18. Tomanek R. J., Doty M. K., Sandra A. Early coronary angiogenesis in response to thyroxine: growth characteristics and upregulation of basic fibroblast growth factor. Circ Res: 1998; 82 587 593 (Pubitemid 28129029)
19. Hall L. C., Salazar E. P., Kane S. R. et al. Effects of thyroid hormones on human breast cancer cell proliferation. The Journal of steroid biochemistry and molecular biology: 2008; 109 57 66 10.1016/j.jsbmb.2007.12.008
20. Conde S. J., Luvizotto R. A., Sibio M. T. et al. Tamoxifen inhibits transforming growth factor-alpha gene expression in human breast carcinoma samples treated with triiodothyronine. Journal of endocrinological investigation: 2008; 31 1047 1051
21. Yen C. C., Huang Y. H., Liao C. Y. et al. Mediation of the inhibitory effect of thyroid hormone on proliferation of hepatoma cells by transforming growth factor-beta. Journal of molecular endocrinology: 2006; 36 9 21 10.1677/jme.1.01911 (Pubitemid 43273661)
22. Tsui K. H., Hsieh W. C., Lin M. H. et al. Triiodothyronine modulates cell proliferation of human prostatic carcinoma cells by downregulation of the B-cell translocation gene 2. The Prostate: 2008; 68 610 619 10.1002/pros.20725 (Pubitemid 351614639)
23. Turkyilmaz A., Eroglu A., Aydin Y. et al. A new risk factor in oesophageal cancer aetiology: hyperthyroidism. Acta chirurgica Belgica: 2010; 110 533 536
24. Iishi H., Tatsuta M., Baba M. et al. Enhancement by thyroxine of gastric carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine in Wistar rats. British journal of cancer: 1993; 68 515 518 (Pubitemid 23258454)
25. Lin H. Y., Tang H. Y., Shih A. et al. Thyroid hormone is a MAPK-dependent growth factor for thyroid cancer cells and is anti-apoptotic. Steroids: 2007; 72 180 187 10.1016/j.steroids.2006.11.014 (Pubitemid 46273502)
26. Valenti T. M., Macchia E., Pisa R. et al. Toxic adenoma and papillary thyroid carcinoma in a patient with Graves' disease. Journal of endocrinological investigation: 1999; 22 701 704 (Pubitemid 29509360)
27. Pellegriti G., Belfiore A., Giuffrida D. et al. Outcome of differentiated thyroid cancer in Graves' patients. The Journal of clinical endocrinology and metabolism: 1998; 83 2805 2809 (Pubitemid 28493780)
28. Hales I. B., McElduff A., Crummer P. et al. Does Graves' disease or thyrotoxicosis affect the prognosis of thyroid cancer. The Journal of clinical endocrinology and metabolism: 1992; 75 886 889
29. Belfiore A., Garofalo M. R., Giuffrida D. et al. Increased aggressiveness of thyroid cancer in patients with Graves' disease. The Journal of clinical endocrinology and metabolism: 1990; 70 830 835
30. Yano Y., Shibuya H., Kitagawa W. et al. Recent outcome of Graves' disease patients with papillary thyroid cancer. European journal of endocrinology/European Federation of Endocrine Societies: 2007; 157 325 329 10.1530/EJE-07-0136 (Pubitemid 47603537)
31. Lee M. Y., Lin K. D., Hsiao P. J. et al. The association of diabetes mellitus with liver, colon, lung, and prostate cancer is independent of hypertension, hyperlipidemia, and gout in Taiwanese patients. Metabolism: 2012; 61 242 249 S0026-0495(11)00200-9 [pii]10.1016/j.metabol.2011.06.020